The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy to treat a potential fatal enzyme deficiency ...

In a report released today, Jason Celino from KeyBanc maintained a Buy rating on PTC (PTC – Research Report). The company’s shares ...

In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a ...

Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...

BOSTON (AP) — BOSTON (AP) — PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share. Earnings, ...

The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...

the global leader in Configuration Lifecycle Management (CLM), today announced a strategic partnership and joint go-to-market strategy with PTC, a global software company that provides solutions ...

Engineering and design software provider PTC (NASDAQ:PTC ... 3D tours or interactive movies. Reviewing a company’s long-term performance can reveal insights into its business quality.

PTC Inc. (PTC) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.20 per share a year ago. These figures are ...

Analysts expect PTC to post earnings of $1.43 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. PTC (NASDAQ ...

Investors interested in PTC should track its annual recurring revenue (ARR) in addition to reported revenue. While reported revenue for a SaaS company can include low-margin items like ...